Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for the link ATLnsider.
Maybe they used Opdivo / Nivolumab (Bristol Meyers Squibb) in the pre-clinical mice study.
ATLnsider,
No recorded version available of LL's presentation on October 27, 2022.
I think the plans changed.
Here is the March 31, 2022 presentation:
P5/55
Protocol 020221, Version 6.2
October 27, 2022
exwannabe,
P.5/55
P.11/55
Happy birthday sentiment!
Thanks for sharing ATLnsider. I agree.
October 26, 2022
Linda Liau:
Thanks for sharing sentiment.
I remember your rebuttal to Adam Feuerstein's FUD about P3 endpoints.
Thanks pgsd!
Research Update in Neuroscience for Neurosurgeons (#RUNN; @SNS_Neurosurg) course in @WHOI led by exemplar surgeon-scientists, Linda Liau (@UCLANsgy), @EAChiocca (@BWHNeurosurgery) and Gerry Grant (@Dukeneurosurg) reveals incredible #neurosurgery research opportunities. pic.twitter.com/M1tsNzklfX
— Russell Lonser, M.D. (@RussellLonser) October 30, 2022
Thanks for the thoughts and prayers, Doc logic.
Sad news, I am so so so sorry to be reading this:
2 h ago
David Jenkinson:
I'm looking forward to seeing the peer reviewed publication describing the results in more detail but this could be a real shifting of the needle for #GBM treatment from @NorthwestBio https://t.co/wtA0W5FIfD
— Research@TheBrainTumourCharity (@BrainTumourCSO) May 26, 2022
0%, IMO.
GermanCol,
you said:
From JA "First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma."
Thanks for the summary ATLnsider.
You said:
Brain Tumour Research
BLOG
News
George Freeman, the APPGBT and this week’s meetings.
28 October 2022 by Hugh Adams
Costas Hadjipanayis
L. Dade Lunsford Professor and Executive Vice-Chair, Director, UPMC Center For Image-Guided Neurosurgery, Co-Director, UPMC Hillman Brain Tumor Center
23h ago
Thank you Dr Linda Liau for spending the day with us in Pittsburgh! Our Pitt residents and faculty enjoyed your talks on immunotherapy for brain tumors and your incredible academic journey. As you pointed out, we can do it all but in stages and of course family first! pic.twitter.com/q3sFVXnWuU
— Costas Hadjipanayis (@hadjiMDPhD) October 27, 2022
Excellent talk by Dr. Liau today. https://t.co/dQYUQWaWoK
— Robert Friedlander (@DrRFriedlander) October 26, 2022
Daniel Yoshor, M.D
Chair of Neurosurgery and VP of Health System at Penn Medicine
8 h ago
Sighting of the great Linda Liau of @UCLANsgy in #philly. She gave a terrific #braintumor research seminar for @PennRadOnc and @PennNSG earlier today. Earned her dinner! pic.twitter.com/6HMPrychje
— Daniel Yoshor, M.D. (@DanielYoshor) October 27, 2022
Linda Liau today:
Linda Liau today:
"This is our next SPORE trial (DC vaccine/poly-ICLC + anti-PD1 + CSF1-Ri in newly diagnosed GBM patients) but we haven't started it yet."
"Targeting Resistance Mechanisms in Glioblastoma"
Linda Liau
October 27
First slide:
UCLA Brain Tumor Specialized Program of Research Excellence (SPORE)
Rational combination strategies and treatment approaches are needed to tackle the problem of brain cancer treatment-induced resistance over time to :
- immunotherapy
- Chemo/Drug therapy
- Radiation therapy
Linda Liau talked about Radiation-induced resistance and Immunotherapy.-Tumor Microenvironment (Project 1)(DCVax + anti-PD-1) This part was also discussed yesterday.
Phase3 DCVax-L trial.
Conference call.
Wednesday, October 26, 2022
4pm-5pm
Linda Liau, MD, PhD, MBA
W. Eugene Stern Professor & Chair
Chair & Executive Medical Director
UCLA Department of Neurosurgery
Director, UCLA Brain Tumor SPORE
David Geffen School of Medicine & UCLA Health
“The Promise of Immunotherapy for Treatment of Glioblastoma”
Long tail (5 years)
LL
"5 years... not just survival but 5 years without recurrence"
Great Lecture.
Mionaer1,
Progression Free Survival Slide.
13 placebo patients at risk 24 months from randomization.
5 events between 24 and 32 months from randomization.
8 placebo patients censored between 24 and 36 months from randomization.
0 placebo patients at risk 36 months from randomization.
NOTE:
5 placebo patients are censored between 0 and 12 months from randomization.
5 placebo patients are censored between 12 and 24 months from randomization.
8 placebo patients are censored between 24 and 36 months from randomization. Total: 18 placebo patients.
Placebo events: 81/99
81 - 64 crossover patients = 17 placebo patients/events. Most were too sick (remember RKmatter's nephew) to cross over or died before evidence of disease progression, IMO.
Remember original first endpoint:
Progression Free Survival (PFS): Time to objective demonstration of
disease progression or death in patients with no evidence of disease progression.
For more information about "censoring": see protocol (60 pages)